-
公开(公告)号：US20190270751A1
公开(公告)日：2019-09-05
申请号：US16411679
申请日：2019-05-14
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D491/056 , C07F7/18 , A61K31/4015 , C07D207/267 , C07D207/08 , C07D209/52 , C07D498/04 , C07D207/273 , C07D263/24 , C07D239/88 , C07D239/86 , C07C69/94 , C07D217/24 , C07D217/22 , C07D217/02 , C07D405/14 , C07D401/14 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , A61K31/40
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20150284405A1
公开(公告)日：2015-10-08
申请号：US14678114
申请日：2015-04-03
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D491/056 , A61K31/4709 , A61K45/06 , C07D405/12 , C07D215/48 , A61K31/47 , A61K31/4725 , C07D417/12 , A61K31/541 , C07D413/12 , A61K31/5377 , C07D207/26 , A61K31/4015 , C07D407/14 , C07D487/04 , C07D403/12 , A61K31/517 , C07D401/12
CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
摘要翻译： 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式Ia结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US09458168B2
公开(公告)日：2016-10-04
申请号：US14678114
申请日：2015-04-03
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D207/26 , C07D401/12 , A61K31/44 , C07D491/056 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D215/48 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , C07F7/18
CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US11702424B2
公开(公告)日：2023-07-18
申请号：US16996117
申请日：2020-08-18
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D491/056 , C07F7/18 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , C07C69/94 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267
CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,
as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.-
公开(公告)号：US20200377511A1
公开(公告)日：2020-12-03
申请号：US16996117
申请日：2020-08-18
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D491/056 , C07F7/18 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US10329302B2
公开(公告)日：2019-06-25
申请号：US15862691
申请日：2018-01-05
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D401/04 , A61K31/47 , C07D491/056 , C07F7/18 , A61K31/4015 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/40 , C07D207/08 , C07D207/267
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US09879022B2
公开(公告)日：2018-01-30
申请号：US15232892
申请日：2016-08-10
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D491/056 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , A61K31/47 , A61K31/517 , A61K31/4015 , A61K31/4709 , A61K31/4725 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D413/12 , C07D417/12 , C07D487/04 , C07D401/14 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , C07F7/18 , A61K31/40 , C07D207/08 , C07D207/267
CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US08575159B2
公开(公告)日：2013-11-05
申请号：US13718928
申请日：2012-12-18
申请人： Pfizer Inc.
发明人： Aranapakam Mudumbai Venkatesan , Zecheng Chen , Christoph Martin Dehnhardt , Osvaldo Dos Santos , Efren Guillermo Delos Santos , Arie Zask , Jeroen Cunera Verheijen , Joshua Aaron Kaplan , David James Richard , Semiramis Ayral-Kaloustian , Tarek Suhayl Mansour , Ariamala Gopalsamy , Kevin Joseph Curran , Mengxiao Shi
IPC分类号： A61K31/535 , C07D413/14
CPC分类号： C07D401/12 , A61K31/5377 , A61K45/06 , C07D251/18 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D451/06 , C07D453/02 , C07D491/113 , C07D498/08
摘要： Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
-
公开(公告)号：US10793579B2
公开(公告)日：2020-10-06
申请号：US16411679
申请日：2019-05-14
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D401/14 , A61K31/47 , A61K31/4709 , A61K31/4725 , C07D491/056 , C07F7/18 , C07D405/14 , C07D217/02 , C07D217/22 , C07D217/24 , C07C69/94 , C07D239/86 , C07D239/88 , C07D263/24 , C07D207/273 , C07D498/04 , C07D209/52 , A61K31/4015 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D207/26 , C07D215/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , A61K31/40 , C07D207/08 , C07D207/267
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
公开(公告)号：US20180127432A1
公开(公告)日：2018-05-10
申请号：US15862691
申请日：2018-01-05
申请人： Pfizer Inc.
发明人： John David Trzupek , Katherine Lin Lee , Mark Edward Bunnage , Seungil Han , David Hepworth , Frank Eldridge Lovering , John Paul Mathias , Nikolaos Papaioannou , Betsy Susan Pierce , Joseph Walter Strohbach , Stephen Wayne Wright , Christoph Wolfgang Zapf , Lori Krim Gavrin , Arthur Lee , David Randolph Anderson , Kevin Joseph Curran , Christoph Martin Dehnhardt , Eddine Saiah , Joel Adam Goldberg , Xiaolun Wang , Horng-Chih Huang , Richard Vargas , Michael Dennis Lowe , Akshay Patny
IPC分类号： C07D491/056 , C07D239/88 , C07D239/86 , C07D263/24 , C07D207/267 , A61K31/40 , C07D207/08 , C07F7/18 , C07D209/52 , C07D498/04 , C07D207/273 , C07C69/94 , C07D217/24 , C07D217/22 , C07D217/02 , C07D405/14 , C07D401/14 , C07D487/04 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D407/14 , C07D215/48 , C07D207/26 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61K31/4015
CPC分类号： C07D491/056 , A61K31/40 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , C07F7/1804
摘要： Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.038 秒)
